Skip to main content

Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52-Week Safety and Efficacy Results From an Open-Label Extension of the Phase 3 Heads Up Study

In brief

Switching to upadacitinib produced skin and itch responses comparable to continued treatment

In a 52-week open-label extension, patients with moderate-to-severe atopic dermatitis who switched from dupilumab to upadacitinib had skin clearance and itch relief generally comparable to those who continued upadacitinib. Safety profiles were also similar between groups, but the open-label design limits how confidently the results can guide treatment choices.

Journal
Journal of the American Academy of Dermatology (Q1)
Published
20 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Vimal H Prajapati, Vivian Laquer, Eingun James Song, Sebastien Barbarot, Lynda Spelman, Laura Huilaja, et al.
PMID
43064158
DOI
10.1016/j.jaad.2026.11.065

Why clinicians should know about it

  • Picked for Dermatology (paper of the day, 21 November 2026): Long-term targeted therapy outcomes after switching in atopic dermatitis

Abstract

BACKGROUND: Despite multiple available systemic therapies for atopic dermatitis (AD), many patients experience inadequate disease control. Safety and efficacy data after switching treatments are needed. OBJECTIVE: To evaluate upadacitinib safety and efficacy in a 52-week open-label extension (OLE) study, continuously or after switching from dupilumab. METHODS: Patients with moderate-to-severe AD who completed 24 weeks of dupilumab 300 mg or upadacitinib 30 mg in the phase 3b Heads Up study were enrolled in an OLE (NCT04195698) and received 52 weeks of upadacitinib 30 mg. We report results through OLE week 52. RESULTS: Upadacitinib safety profiles were similar among patients who received continuous upadacitinib treatment and patients who switched from dupilumab to upadacitinib, consistent with previous AD studies. Clinical responses for skin clearance and itch relief were sustained during the OLE with continuous upadacitinib. For patients who switched from dupilumab to upadacitinib, clinical response at the end of the OLE was generally comparable to patients who received continuous upadacitinib. LIMITATIONS: Open-label study. CONCLUSION: Upadacitinib may offer a safe, effective therapeutic option for managing moderate-to-severe AD. Skin and itch outcomes at the end of the OLE were generally comparable between patients who switched from dupilumab to upadacitinib and those who received continuous upadacitinib.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.